BeOne Medicines (ONC) Current Deferred Revenue (2015 - 2023)
BeOne Medicines (ONC) posted quarterly Current Deferred Revenue of $159.0 million for Q2 2023, down 2.67% year-over-year from $163.4 million in Q2 2022, and down 14.26% quarter-over-quarter from $185.5 million in Q1 2023.
BeOne Medicines (ONC) Current Deferred Revenue (2015 - 2023) Analysis & Trends
BeOne Medicines (ONC) has reported Current Deferred Revenue for 8 consecutive years, with $159.0 million the latest figure, recorded in Q2 2023.
- In Q2 2023, Current Deferred Revenue fell 2.67% year-over-year to $159.0 million; the TTM figure through Jun 2023 stood at $159.0 million (down 2.67% YoY), while the FY2022 annual figure was $213.9 million, down 28.71% from the prior year.
- Current Deferred Revenue fell to $159.0 million in Q2 2023 per ONC's latest filing, from $185.5 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $300.0 million in Q4 2021 and bottomed at $17.5 million in Q1 2019.
- Historically, Current Deferred Revenue has averaged $141.4 million across 4 years, with a median of $159.0 million in 2023.
- On a YoY basis, Current Deferred Revenue climbed as much as 156.89% in 2022 and fell as far as 28.71% in 2022.
- BeOne Medicines' Current Deferred Revenue stood at $17.5 million in 2019, then soared by 1613.89% to $300.0 million in 2021, then dropped by 28.71% to $213.9 million in 2022, then decreased by 25.64% to $159.0 million in 2023.
- Business Quant data shows ONC's Current Deferred Revenue at $159.0 million in Q2 2023, $185.5 million in Q1 2023, and $213.9 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 159.03 Mn |
| Mar 31, 2023 | 185.48 Mn |
| Dec 31, 2022 | 213.86 Mn |
| Sep 30, 2022 | 144.98 Mn |
| Jun 30, 2022 | 163.40 Mn |
| Mar 31, 2022 | 163.66 Mn |
| Dec 31, 2021 | 300.00 Mn |
| Sep 30, 2021 | 72.63 Mn |
| Jun 30, 2021 | 63.61 Mn |
| Mar 31, 2021 | 71.65 Mn |
| Mar 31, 2019 | 17.50 Mn |
| Dec 31, 2018 | 18.14 Mn |
| Sep 30, 2018 | 16.71 Mn |
| Jun 30, 2018 | 15.30 Mn |
| Mar 31, 2018 | 14.01 Mn |
| Dec 31, 2017 | 12.23 Mn |
| Sep 30, 2017 | 9.13 Mn |
| Mar 31, 2016 | 393,000.00 |
| Dec 31, 2015 | 1.07 Mn |